Science 37
- π¦Became a unicorn2021
- πPeak valuation$1.4 Billion β21
- πBecame a UnitardMar 2024
- πΈLast valuation~$42M
Total raised averaged per day over approximately 9.7 years from founding to bankruptcy or shutdown. This is not measured cash burn. Methodology
The rise & fall
5 moments Β· 2014β2024The key moments.
How it happened
Science 37 built a platform for running clinical trials remotely, with patients at home. It merged with the SPAC LifeSci Acquisition II Corp in October 2021 at an announced $1.05B enterprise value, and the stock traded at a market capitalization of roughly $1.4-1.6B late that year.
When pandemic-era trial volumes fell and sales cycles lengthened, revenue stalled and the shares collapsed, forcing a 1-for-20 reverse split in December 2023 to keep its Nasdaq listing. In January 2024 the telehealth and diagnostics company eMed agreed to buy Science 37 in an all-cash tender offer of $5.75 a share, valuing the equity at about $38M, and the deal closed that March.
Glassdoor reviews from the SPAC years were among the lowest here, describing disorganized leadership and repeated rounds of layoffs.
Employee accounts paraphrase anonymous, unverified reviews posted publicly on Glassdoor β. See our methodology.
Source: BioSpace / company: de-SPAC with LifeSci Acquisition II Corp consummated Oct 6, 2021 (announced May 7, 2021) at a ~$1.05B announced enterprise value; the FY2021 10-K shows 115,493,635 shares, and late-2021 prices of ~$9.37-$12.47 imply a ~$1.1-1.5B traded market capitalization (MedCity / Global Genes cite ~$1.6B in Nov 2021). GlobeNewswire / SEC (Jan 29, 2024): eMed all-cash tender at $5.75/share (~$38M equity) via Marlin Merger Sub, after a 1-for-20 reverse split (Dec 8, 2023); deal completed Mar 12, 2024. Peak keyed to the late-2021 traded market cap. Founded 2014 by dermatologists Noah Craft and Belinda Tan; David Coman joined as CEO in 2019.
Founders & leadership
Current roles as self-reported on LinkedIn, retrieved 2026-10-13. See our methodology.
Disclosed investors (19)
Historical funding participation; lists may be incomplete and do not establish current ownership or investor losses.
* Lead in a funding round Β· Crunchbase β Β· 2026-10-13 Β· Methodology Β· Leaderboard